汉森制药受益中药新政，股价波动上涨，财报显示营收增但净利降

Group 1: Policy Developments - The Ministry of Industry and Information Technology and seven other departments jointly issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to cultivate 60 high-standard traditional Chinese medicine raw material production bases and establish 5 innovation centers by 2030, which brings policy benefits to the industry [1] Group 2: Stock Performance - Over the past 7 trading days (February 6 to 12, 2026), the stock price of Hansen Pharmaceutical showed a volatile upward trend, with a peak closing price of 8.02 yuan on February 9, reflecting a 5.67% increase [2] - The stock experienced a cumulative increase of 10.14% during this period, with a price fluctuation of 22.46% [2] - As of February 12, the latest stock price was 7.60 yuan, down 2.56% from the previous day, with a notable net outflow of 27.25 million yuan from institutional investors [2] Group 3: Financial Performance - Hansen Pharmaceutical reported a revenue of 741 million yuan for Q3 2025, representing a year-on-year growth of 6.75%, while the net profit attributable to shareholders decreased by 36.88% to 82.52 million yuan [3] - The gross margin remained high at 77.04%, above the industry average, but the net profit margin declined to 11.14% due to increased sales and management expenses [3] - Operating cash flow improved significantly, increasing by 16.42% to 162 million yuan, and the controlling shareholder's pledge ratio decreased to 4.72%, reducing equity pledge risk [3] Group 4: Institutional Insights - Institutional interest in Hansen Pharmaceutical is relatively low, with a neutral sentiment prevailing in the latest market discussions [4] - Century Securities noted that the traditional Chinese medicine industry is expected to undergo a reshuffle under policy guidance, favoring companies with a strong reserve of classic formulas [4] - Current institutional ratings are predominantly neutral, with fund ownership at only 0.02%, highlighting the need to monitor the actual impact of subsequent policy implementations on the company's fundamentals [4]